Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore

BACKGROUND: Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in the adjuvant setting in Southeast Asia. METHODS: So...

Descripción completa

Detalles Bibliográficos
Autor principal: de Lima Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118893/
https://www.ncbi.nlm.nih.gov/pubmed/21586176
http://dx.doi.org/10.1186/1471-2407-11-178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118893/
https://www.ncbi.nlm.nih.gov/pubmed/21586176
http://dx.doi.org/10.1186/1471-2407-11-178

Ejemplares similares